GlassScriptPhysician profile
Stevie Camp
NPI 1275181323
$24,581.04
in general payments reported to CMS, 2019-2025
71 companies · $5,249 in 2025
The $5,249 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,926 · 2022: $6,452 · 2023: $4,139 · 2024: $3,814 · 2025: $5,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,405.35 |
| Education | $797.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $3,118.77 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Janssen Biotech, INC. | $1,894.08 | 2021-2025 | Carvykti, Darzalex, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $1,632.42 | 2021-2025 | Enhertu, Imfinzi, Lynparza |
| Pfizer INC. | $1,468.02 | 2021-2025 | |
| Celgene Corporation | $1,319.93 | 2021-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $1,302.85 | 2022-2025 | |
| Daiichi Sankyo INC. | $1,012.39 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Incyte Corporation | $780.86 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Glaxosmithkline, LLC. | $779.19 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $631.96 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Seagen INC. | $618.18 | 2021-2025 | Tukysa, Padcev, Tivdak |
| Eisai INC. | $615.32 | 2021-2025 | |
| Abbvie INC. | $569.37 | 2021-2025 | |
| Astellas Pharma US INC | $562.24 | 2021-2025 | Padcev, Xospata, Xtandi |
| Genentech USA, INC. | $450.81 | 2021-2025 | Phesgo, Polivy, Tecentriq Hybreza |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $406.23 | 2021-2023 | Lumakras |
| Genzyme Corporation | $364.91 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $360.66 | 2023-2025 | Orgovyx |
| Pharmacyclics LLC, An Abbvie Company | $355.84 | 2021-2023 | Epkinly, Imbruvica |
| Regeneron Healthcare Solutions, INC. | $325.26 | 2022-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $316.20 | 2022-2025 | Iclusig, Alunbrig, Ninlaro |
| Alexion Pharmaceuticals, INC. | $296.69 | 2021-2024 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $279.04 | 2021-2025 | Fotivda |
| Servier Pharmaceuticals LLC | $253.48 | 2022-2025 | |
| Epizyme, INC. | $244.90 | 2021-2023 | Tazverik |
| Kite Pharma, INC. | $229.36 | 2021-2023 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $228.32 | 2021-2025 | Opdivo |
| Pharmacosmos Therapeutics INC. | $221.42 | 2023-2025 | Monoferric, Cosela |
| Deciphera Pharmaceuticals INC. | $221.29 | 2021-2025 | Qinlock, Romvimza |
| Emd Serono, INC. | $220.36 | 2021-2024 | Bavencio |
| Taiho Oncology, INC. | $209.51 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $175.45 | 2021-2025 | Onivyde |
| Gilead Sciences, INC. | $175.29 | 2022-2025 | Trodelvy |
| Adc Therapeutics America, INC. | $169.02 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $168.14 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $164.33 | 2021-2023 | Myrisk |
| Tersera Therapeutics LLC | $160.37 | 2023-2025 | Zoladex |
| Exelixis INC. | $154.93 | 2021-2025 | Cabometyx |
| Array Biopharma INC | $145.00 | 2021-2025 | Braftovi, Mektovi, Xalkori |
| Tempus Ai, INC | $135.05 | 2024-2025 | Xt Cdx |
| Mirati Therapeutics, INC. | $127.34 | 2023-2024 | Krazati |
| Jazz Pharmaceuticals INC. | $121.87 | 2022 | |
| Sobi, INC | $114.04 | 2023-2025 | |
| Stemline Therapeutics INC. | $112.69 | 2023-2025 | Orserdu |
| Morphosys, US INC. | $107.83 | 2022-2023 | Monjuvi |
| Rigel Pharmaceuticals, INC. | $107.48 | 2024 | Rezlidhia, Tavalisse |
| Sanofi-Aventis U.S. LLC | $99.99 | 2021 | |
| Adaptive Biotechnologies Corporation | $96.00 | 2022-2025 | Clonoseq |
| Immunogen, INC. | $89.91 | 2023 | Elahere |
| Janssen Pharmaceuticals, INC | $89.76 | 2021-2025 | Xarelto |
| Beigene USA, INC. | $85.81 | 2021-2025 | Brukinsa |
| Myovant Sciences INC. | $77.64 | 2021-2022 | |
| Kyowa Kirin, INC. | $70.28 | 2021-2022 | |
| Genmab U.S., INC. | $65.27 | 2024-2025 | Epkinly |
| G1 Therapeutics, INC. | $62.56 | 2023 | Cosela |
| Clovis Oncology, INC. | $53.07 | 2021 | |
| Syndax Pharmaceuticals, INC. | $46.49 | 2025 | |
| Dova Pharmaceuticals | $44.20 | 2021 | |
| Legend Biotech USA INC. | $35.18 | 2025 | Carvykti |
| Beone Medicines USA, INC. | $29.39 | 2025 | Brukinsa |
| Foundation Medicine, INC. | $23.96 | 2021 | |
| Blueprint Medicines Corporation | $23.75 | 2025 | Ayvakit |
| Agios Pharmaceuticals, INC. | $22.07 | 2025 | Pyrukynd |
| Iovance Biotherapeutics, INC. | $20.85 | 2025 | Amtagvi |
| Puma Biotechnology, INC. | $20.40 | 2025 | |
| Karyopharm Therapeutics INC. | $20.02 | 2021 | |
| Invivyd INC | $19.33 | 2025 | Pemgarda |
| Geron Corporation | $14.82 | 2025 | Rytelo |
| Tolmar, INC. | $14.26 | 2025 | Rubraca |
| Pharmaand Gmbh | $14.26 | 2025 | Rubraca |
| Cti Biopharma Corp. | $13.08 | 2023 | Vonjo |
Drugs and devices associated with these payments
Enhertu $1,033Reblozyl $904Kisqali $556Carvykti $542Orgovyx $436Darzalex $388Pluvicto $349Rybrevant $322Ojjaara $313Keytruda $308Tecvayli $297Jakafi $296Erleada $277Elahere $274Lynparza $239Venclexta $236Jemperli $235Tukysa $226Lonsurf $210Inqovi $210Imfinzi $207Ibrance $192Libtayo $188Opdivo $188Qinlock $183Padcev $179Yescarta $171Monjuvi $167Monoferric $166Zoladex $160Piqray $160Sarclisa $153Xtandi $136Xt Cdx $135Fabhalta $134Trodelvy $133Lenvima $130Zejula $128Krazati $127Nubeqa $122Fotivda $121Lutathera $119Cosela $118Tibsovo $116Orserdu $113Talvey $110Adcetris $109Rezlidhia $107Tavalisse $107Injectafer $105Epkinly $104Bavencio $98.16Elrexfio $96.69Talzenna $94.19Tivdak $93.15Cabometyx $91.91Idhifa $91.82Calquence $90.85Brukinsa $88.04Xofigo $87.39Jaypirca $86.74Verzenio $86.74Bosulif $86.47Phesgo $84.34Romvimza $78.80Scemblix $77.45Polivy $77.06Zynyz $72.65Vonjo $70.52Iclusig $67.72Alunbrig $66.41Imbruvica $65.94Ninlaro $61.59Clonoseq $57.51Inlyta $56.71Doptelet $56.60Keytruda Qlex $55.85Pemazyre $51.49Retevmo $48.82Xospata $44.69Braftovi $44.18Datroway $42.50Tecentriq Hybreza $40.16Mektovi $39.45Mekinist $38.38Lunsumio $35.01Myrisk $34.89Ultomiris $34.76Lumakras $29.49Onivyde $29.39Fruzaqla $29.32Rubraca $28.52Welireg $26.69Pomalyst $25.86Tazverik $24.80Blenrep $24.04Ayvakit $23.75Alecensa $22.28Tecentriq $22.28Pyrukynd $22.07
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stevie Camp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.